What this covers

Marcia Angell, a physician and former editor of the New England Journal of Medicine, speaks with Russ Roberts about the structure of incentives that, she argues, has turned large pharmaceutical companies away from genuine science and toward marketing and regulatory manipulation. The conversation traces how the Bayh-Dole Act allowed drug firms to license discoveries from publicly funded research rather than conduct their own, how companies design and control clinical trials while suppressing negative results, and how marketing budgets—often double research spending—and payments to physicians shape prescribing patterns more than drug efficacy. Angell's central claim is that most new drugs sold are not innovations at all, but slight modifications of existing ones: me-too drugs engineered mainly to extend patent life and market exclusivity.

The conversation spans several mechanisms of this system. Angell describes how disease mongering—marketing conditions themselves alongside drugs, sometimes by lowering diagnostic thresholds—expands markets. She details publication bias, where the FDA keeps negative trial results proprietary, leaving doctors and patients to see only published positive findings. She argues that placebo-controlled trials prove only that a drug beats nothing, not that it beats existing treatments, and that active comparator vs placebo designs should be required. Roberts raises the third-party payment problem—that insurance removes price discipline on both doctors and patients—while Angell points to regulatory capture at the FDA, where user fees from companies now fund over half the drug-approval division's budget. She illustrates with specific cases: the Vioxx deaths, the Prilosec-to-Nexium switch, and the 2005 COX-2 advisory committee stacked with conflicts of interest. Throughout, she contrasts the innovation vs development distinction, arguing that companies excel at the latter—expensive late-stage work—but have abandoned the former.

Sharpest takeaway

Angell argues that large pharmaceutical companies do little genuine innovation, instead free-riding on publicly funded research while using marketing, regulatory capture, and corruption of academic medicine to sell expensive 'me-too' drugs of no proven superiority.

  • The Bayh-Dole Act let drug companies license discoveries from publicly funded labs rather than do their own basic research
  • Companies control clinical trial design and suppress negative results, biasing the evidence doctors and the public see
  • Marketing spending (twice R&D) and physician payments shape prescribing more than drug quality

The argument · threads4 threads · 32 claims
0.85

Third-party payment and industry influence remove price discipline, enabling expensive drugs over cheaper equivalents.

1 pointcentrality 5/5
  • A major part of the problem beyond drug-company profit motive is that Americans pay for most medical care with other people's dollars, which removes the price discipline that would lead patients to choose cheap equivalent drugs and allows doctors who receive industry gifts to prescribe expensive new drugs.

    “the other part of the problem is we pay for much of our medical care with other people's dollars. And that allows the corruption of the process.”

0.85

Government's large role in healthcare inevitably privileges groups and generates self-reinforcing political capture.

1 pointcentrality 5/5
  • Once government's large role in healthcare privileges certain groups, it becomes very hard to prevent the resulting political power from growing and feeding back on itself in unhealthy ways, a structural dynamic also seen in how the financial sector captured both political parties.

    “Once you privilege certain groups, which is inevitably going to happen with something as large as government's role in the health care system, it's going to be very hard to keep the political power that results from that from getting larger, and then feeding back on itself in unhealthy ways.”

0.71

Disclosure and individual choice, not removal of risky drugs, is the appropriate standard for drug safety policy.

1 pointcentrality 4/5
  • Rather than removing risky drugs from the market, the better approach is to disclose the risks and let people act like adults and choose for themselves, because a standard of only perfectly safe drugs would leave us with very few drugs.

    “My preference would have been to keep them all on the market anyway and let people act like adults: Tell the risks and let them choose... if our only standard is perfectly safe drugs, we are not going to have many drugs.”

0.44

Assigning responsibility to 'government' as a single entity obscures its fragmented structure and does not guarantee outcomes.

1 pointcentrality 2/5
  • Appeals to 'government responsibility' are weak because there is no single creature called The Government; it is 535 members of Congress, the President, and agencies, connected only tenuously to citizens, so assigning it a 'responsibility' does not guarantee good outcomes.

    “there's no such thing as a creation, a creature called The Government. It's the 535 members of Congress, the President, the agencies, and everybody else.”